Summary:
A local research group is evaluating the safety and effectiveness of an investigational biological medication for the treatment of moderate to severe PsA.
Criteria:Be at least 18 years old or older
Have been diagnosed with PsA with symptom onset for at least 6 months
Have diagnosis of plaque psoriasis
Have demonstrated an inadequate response or intolerance to synthetic disease modifying anti-rheumatic drugs
Qualified Participants May Receive:
Qualified participants may receive reimbursement for time and travel. Study-related care and study-related medication may be provided at no cost.